Capecitabine and oxaliplatin study for cancer patients
Part of Cancer, Digestive system, Skin clinical trials.
This study looks at how your genes affect the way your body handles the chemotherapy drug capecitabine when it's taken with oxaliplatin. The goal is to understand if certain genetic differences can impact drug levels, which may help personalize treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are about to start treatment with capecitabine and oxaliplatin as part of your standard cancer care.
- Your doctor has confirmed you are healthy enough for this treatment.
- You are able to understand the study and sign a consent form.
- You do not have a known DPYD gene variant that affects how your body processes capecitabine.
- You have not had prior treatment with fluoropyrimidines (a class of chemotherapy that includes capecitabine).
- You do not have a condition that affects stomach absorption, like gastric bypass or complete stomach removal (but having an esophagectomy is okay).
- You are not using DPD inhibitors or allopurinol.
- You are not pregnant at the start of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
This study looks at how genetic differences in Egyptian people with breast or colorectal cancer might affect the side effects of the chemotherapy drug capecitabine. The goal is to understand why some people have more side effects than others.
This trial tests whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine plus oxaliplatin) based on a liver enzyme test can improve safety and effectiveness for people with gastrointestinal cancer who are starting this type of chemo for the first time.
This trial checks if adjusting the dose of chemotherapy drugs 5-FU or capecitabine based on your DPYD genetic results can improve safety and effectiveness. It’s for people with cancer who are about to start these drugs for the first time.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
Hear when a new Gastric (Cardia, Body) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.